To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
NCT ID: NCT05732766
Last Updated: 2023-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
1800 participants
INTERVENTIONAL
2023-02-04
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Population: A total of 1800 participants will be enrolled in three descending age groups(Group I- ≥18, Group II: ≥5 to \<18 and Group III: ≥1 to \<5). In each group,600 participants will be enrolled and will receive two doses of Hillchol® (BBV131) vaccine two weeks apart.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
NCT05507229
A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children
NCT00760825
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™
NCT04760236
Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine
NCT02823899
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
NCT00419133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Population: A total of 1800 participants will be enrolled in three descending age groups(Group I- ≥18, Group II: ≥5 to \<18 and Group III: ≥1 to \<5). In each group,600 participants will be enrolled and will receive two doses of Hillchol® (BBV131) vaccine two weeks apart.
Study Objectives:
Primary Objectives:
1)To evaluate the frequency and severity of all solicited and unsolicited adverse events after administration of two doses of Hillchol® (BBV131) among all three age groups.
End points:
1. Immediate reaction: Within 30mins of administration of each dose.
2. Incidence, intensity, and the causality of all solicited adverse events during the 7-day follow up period after each dose.
3. Incidence, intensity, and the causality of unsolicited adverse events during the 7-day follow up period after each dose.
4. Incidence, intensity, and the causality of all adverse events and Serious Adverse Events (SAEs) during the entire study period.
Study design:
In this study, a total sample size of 1800 participants will be enrolled in three age groups and administered with Hillchol® (BBV131).
A) Group-I (Age: ≥18): In this group, a total of 600 participants aged ≥18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
B) Group-II (Age: ≥5 to \<18): In this group, a total of 600 participants aged ≥5 to \<18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
C)Group-III (Age: ≥1 to \<5): In this group, a total of 600 participants aged ≥1 to \<5 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
Eligibility Criteria:
Inclusion Criteria:
1. Participants /Legally acceptable representatives who have the ability to provide written informed consent.
2. Participants of either gender of age ≥ 1 year.
3. Expressed interest and availability to fulfill the study requirements.
1. Willing to receive two doses of the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
Exclusion:
1. Any history of anaphylaxis in relation to vaccination.
2. Participants with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual is thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator.
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours before study initiation.
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week before study initiation.
7. Other vaccination within 4 weeks before study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months before study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
13. History of any psychiatric condition likely to affect participation in the study.
14. Suspected or known current alcohol abuse is defined by an alcohol intake of greater than 42 units every week.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the study or would render the subject unable to comply with the protocol.
Study Procedure:
Visit 1:Baseline (Day 0):If eligible, study participants will attend the OPD for a physical and general examination. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse events. Diary cards will be distributed to all the participants to record the adverse events after vaccination.
Day 1-7: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status
. Visit 2 (Day 14+2):Study participants will return to the OPD for physical, and general examination. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse events. Diary cards will be distributed to all the participants to record the adverse events after vaccination.
Day 15-21: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status.
Visit 3 (Day 28+2):Study participants will return to the OPD for physical and general examination. Diary cards will be collected from all the participants to record the adverse events after vaccination.
Visit 4: (Day 56±7):Study participants will be contacted telephonically and followed up by the site to know their current health status and all the safety-related issues will be recorded.
Visit 5 (Day 90±7):-Study participants will return to the OPD for physical and general examination. If any adverse events it will be recorded.
Visit 6 (Day 180±7):Study participants will be contacted telephonically and followed up by the site to know their current health status and all the safety-related issues will be recorded.
Unscheduled visits:
If any subject develops any adverse or serious adverse event or is concerned about his/her health, they will be advised to visit the study site during the study follow-up period. All unscheduled visits and details of adverse events will be documented in the source document. Concomitant medications, if any, will also be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group-I (Age: ≥18)
Group-I (Age: ≥18) In this group, a total of 600 participants aged ≥18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
Hillchol vaccine
Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Group-II (Age: ≥5 to <18)
Group-II (Age: ≥5 to \<18): In this group, a total of 600 participants aged ≥5 to \<18 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14.
Hillchol vaccine
Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Group-III (Age: ≥1 to <5)
Group-III (Age: ≥1 to \<5): In this group, a total of 600 participants aged ≥1 to \<5 will be enrolled and administered two doses of Hillchol® (BBV131) on day 0 and 14
Hillchol vaccine
Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hillchol vaccine
Hillchol® (BBV131) (The whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants of either gender of age \> 1 year.
3. Expressed interest and availability to fulfill the study requirements.
1. Willing to receive two doses of the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
Exclusion Criteria
2. Participants with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual is thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator.
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours before study initiation
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week before study initiation.
7. Other vaccination within 4 weeks before study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months before study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
1 Year
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bharat Biotech International Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King George Hospital, Visakhapatnam
Visakhapatnam, Andhra Pradesh, India
Rajarajeswari Medical College and Hospital
Kambīpura, Bangalore, India
All India Institute of Medical Sciences, Patna
Patna, Bihar, India
Pt BD Sharma,PGIMS/UHS. Rohtak
Rohtak, Haryana, India
Jeevan Rekha Hospital, Belgaum
Belagavi, Karnataka, India
Gillurkar Multispecialty Hospital
Nagpur, Maharashtra, India
Malla Reddy Narayana Multi Speciality Hospital
Hyderabad, Telangana, India
Rana Hospital Pvt Ltd
Gorakhpur, Uttar Pradesh, India
New Leelamani Hospital Pvt Ltd
Kanpur, Uttar Pradesh, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hillchol®(BBV131) Safety
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.